Appetite-related gut peptides, ghrelin, PYY, and GLP-1 in obese women with and without binge eating disorder (BED).
BED is characterized by overeating with a loss of control. The primary aim of the study was to measure plasma concentrations of three key gut peptides influencing hunger (ghrelin) and satiety (PYY, GLP-1) to ascertain potential abnormalities in BED. The participants were 10 obese BED and 9 obese nonBED premenopausal women. They did not differ in age, 30.1+/-8.1 SD, BMI, 36.2+/-5.9, or % body fat, 43.3+/-5.7. Following a13-h overnight fast, blood was drawn (-15, 0, 5, 15, 30, 60, 90, 120 min) for measurement of total plasma concentrations of ghrelin, PYY and GLP-1, pre and post ingestion of a nutritionally complete liquid meal (1256 kJ) at 9 am (0-5 min). Ratings of hunger and fullness preceded each blood draw. Ghrelin was significantly lower premeal at -15 min (P=.05) and postmeal at 90 min (P=.027) and 120 min (P=.025) in the BED group as compared to the nonBED group. Ghrelin also declined less postprandially in the BED group (P=.019) with a longer time to the nadir value (P=.004). However, fasting and meal-related changes in levels of PYY and GLP-1 did not differ between the groups nor did ratings of hunger and fullness. Following a randomized cognitive behavior and dietary intervention, the ghrelin values in BED normalized. Prior to treatment, the lower fasting ghrelin in BED may be a consequence of down regulation by overeating. The lack of differences in the satiety promoting hormones, PYY and GLP-1, makes them unlikely contributors to the binge eating in BED.
Geliebter
Allan
A
Department of Psychiatry, Columbia University-College of Physician and Surgeons, New York, NY 10025, USA. ag58@columbia.edu
Hashim
Sami A
SA
Gluck
Marci E
ME
D000328:Adult; D000704:Analysis of Variance; D001069:Appetite Regulation / Q000502:physiology*; D052018:Bulimia Nervosa / Q000097:blood* / Q000150:complications / Q000628:therapy; D015928:Cognitive Behavioral Therapy; D003376:Counseling; D005260:Female; D054439:Ghrelin / Q000097:blood*; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D006801:Humans; D016014:Linear Models; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000628:therapy; D019894:Peptide YY / Q000097:blood*; D019518:Postprandial Period / Q000502:physiology; D012527:Satiation / Q000502:physiology
D054439:Ghrelin; D019894:Peptide YY; D052216:Glucagon-Like Peptide 1